nodes	percent_of_prediction	percent_of_DWPC	metapath
Phylloquinone—BGLAP—urine—kidney cancer	0.132	0.581	CbGeAlD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—FOSL2—kidney cancer	0.0413	0.117	CbGpPWpGaD
Phylloquinone—Scleroderma—Paclitaxel—kidney cancer	0.0353	0.089	CcSEcCtD
Phylloquinone—BGLAP—renal system—kidney cancer	0.0322	0.142	CbGeAlD
Phylloquinone—GGCX—renal system—kidney cancer	0.0315	0.139	CbGeAlD
Phylloquinone—BGLAP—kidney—kidney cancer	0.0312	0.138	CbGeAlD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—FOSL1—kidney cancer	0.0275	0.078	CbGpPWpGaD
Phylloquinone—Vitamin E—GSTP1—kidney cancer	0.024	1	CrCbGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—JUND—kidney cancer	0.0213	0.0602	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—SMARCB1—kidney cancer	0.018	0.051	CbGpPWpGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—JUNB—kidney cancer	0.0145	0.041	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—MITF—kidney cancer	0.0127	0.0359	CbGpPWpGaD
Phylloquinone—Hyperbilirubinaemia—Pazopanib—kidney cancer	0.0119	0.0299	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—IL13—kidney cancer	0.00944	0.0268	CbGpPWpGaD
Phylloquinone—Swelling—Temsirolimus—kidney cancer	0.00941	0.0237	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—BIRC5—kidney cancer	0.00884	0.0251	CbGpPWpGaD
Phylloquinone—Inflammation—Everolimus—kidney cancer	0.00877	0.0221	CcSEcCtD
Phylloquinone—Necrosis—Dactinomycin—kidney cancer	0.00857	0.0216	CcSEcCtD
Phylloquinone—Inflammation—Erlotinib—kidney cancer	0.00846	0.0213	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—HIF1A—kidney cancer	0.00777	0.022	CbGpPWpGaD
Phylloquinone—GGCX—Post-translational protein modification—MUC4—kidney cancer	0.00751	0.0213	CbGpPWpGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—KDR—kidney cancer	0.00743	0.0211	CbGpPWpGaD
Phylloquinone—Phlebitis—Vinblastine—kidney cancer	0.0072	0.0182	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—EGR1—kidney cancer	0.00715	0.0203	CbGpPWpGaD
Phylloquinone—GGCX—Post-translational protein modification—ST3GAL2—kidney cancer	0.00714	0.0202	CbGpPWpGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CDKN2A—kidney cancer	0.00673	0.0191	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—MET—kidney cancer	0.00651	0.0184	CbGpPWpGaD
Phylloquinone—Hyperbilirubinaemia—Gemcitabine—kidney cancer	0.00627	0.0158	CcSEcCtD
Phylloquinone—Necrosis—Paclitaxel—kidney cancer	0.00608	0.0153	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCND1—kidney cancer	0.00569	0.0161	CbGpPWpGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—JUN—kidney cancer	0.00567	0.0161	CbGpPWpGaD
Phylloquinone—Phlebitis—Dactinomycin—kidney cancer	0.00567	0.0143	CcSEcCtD
Phylloquinone—Injection site reaction—Gemcitabine—kidney cancer	0.00567	0.0143	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—RAF1—kidney cancer	0.00566	0.016	CbGpPWpGaD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—RELA—kidney cancer	0.00564	0.016	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—CDH1—kidney cancer	0.00564	0.016	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—MET—kidney cancer	0.00554	0.0157	CbGpPWpGaD
Phylloquinone—Hyperbilirubinaemia—Paclitaxel—kidney cancer	0.00525	0.0132	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—CD4—kidney cancer	0.00524	0.0148	CbGpPWpGaD
Phylloquinone—Immune system disorder—Temsirolimus—kidney cancer	0.00519	0.0131	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—EIF5B—kidney cancer	0.00514	0.0146	CbGpPWpGaD
Phylloquinone—Flushing—Pazopanib—kidney cancer	0.00502	0.0127	CcSEcCtD
Phylloquinone—Erythema—Temsirolimus—kidney cancer	0.005	0.0126	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—CDKN1B—kidney cancer	0.00492	0.0139	CbGpPWpGaD
Phylloquinone—Injection site pain—Capecitabine—kidney cancer	0.0048	0.0121	CcSEcCtD
Phylloquinone—Injection site reaction—Paclitaxel—kidney cancer	0.00475	0.012	CcSEcCtD
Phylloquinone—Erythema—Pazopanib—kidney cancer	0.00471	0.0119	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—CUL7—kidney cancer	0.00458	0.013	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—HSPA9—kidney cancer	0.00437	0.0124	CbGpPWpGaD
Phylloquinone—Hyperbilirubinaemia—Capecitabine—kidney cancer	0.00431	0.0109	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Gemcitabine—kidney cancer	0.00428	0.0108	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CDKN2A—kidney cancer	0.00424	0.012	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—JUN—kidney cancer	0.00419	0.0119	CbGpPWpGaD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—POMC—kidney cancer	0.00417	0.0118	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—RAF1—kidney cancer	0.00409	0.0116	CbGpPWpGaD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—MAPK3—kidney cancer	0.00408	0.0116	CbGpPWpGaD
Phylloquinone—Anaphylactic shock—Temsirolimus—kidney cancer	0.00408	0.0103	CcSEcCtD
Phylloquinone—Inflammation—Capecitabine—kidney cancer	0.00404	0.0102	CcSEcCtD
Phylloquinone—Phlebitis—Paclitaxel—kidney cancer	0.00402	0.0101	CcSEcCtD
Phylloquinone—Flushing—Everolimus—kidney cancer	0.00397	0.01	CcSEcCtD
Phylloquinone—Swelling—Paclitaxel—kidney cancer	0.00393	0.00991	CcSEcCtD
Phylloquinone—Injection site reaction—Capecitabine—kidney cancer	0.0039	0.00982	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—MAPK1—kidney cancer	0.00388	0.011	CbGpPWpGaD
Phylloquinone—Immune system disorder—Everolimus—kidney cancer	0.00386	0.00973	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CDKN1B—kidney cancer	0.00375	0.0106	CbGpPWpGaD
Phylloquinone—Erythema—Everolimus—kidney cancer	0.00372	0.00938	CcSEcCtD
Phylloquinone—Hyperhidrosis—Pazopanib—kidney cancer	0.00372	0.00937	CcSEcCtD
Phylloquinone—Dyspnoea—Temsirolimus—kidney cancer	0.00364	0.00918	CcSEcCtD
Phylloquinone—Erythema—Erlotinib—kidney cancer	0.00359	0.00905	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CCND1—kidney cancer	0.00358	0.0101	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—JUN—kidney cancer	0.00357	0.0101	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—MUC4—kidney cancer	0.00356	0.0101	CbGpPWpGaD
Phylloquinone—Pain—Temsirolimus—kidney cancer	0.00349	0.0088	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—MAPK3—kidney cancer	0.00347	0.00982	CbGpPWpGaD
Phylloquinone—Flushing—Sorafenib—kidney cancer	0.00344	0.00868	CcSEcCtD
Phylloquinone—Dyspnoea—Pazopanib—kidney cancer	0.00343	0.00865	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—RELA—kidney cancer	0.00343	0.00971	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—ST3GAL2—kidney cancer	0.00339	0.0096	CbGpPWpGaD
Phylloquinone—Immune system disorder—Sorafenib—kidney cancer	0.00335	0.00845	CcSEcCtD
Phylloquinone—Flushing—Sunitinib—kidney cancer	0.00331	0.00835	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—EEF2—kidney cancer	0.00331	0.00938	CbGpPWpGaD
Phylloquinone—Phlebitis—Capecitabine—kidney cancer	0.0033	0.00833	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—MAPK1—kidney cancer	0.0033	0.00934	CbGpPWpGaD
Phylloquinone—Pain—Pazopanib—kidney cancer	0.00329	0.00829	CcSEcCtD
Phylloquinone—Erythema—Sorafenib—kidney cancer	0.00323	0.00814	CcSEcCtD
Phylloquinone—Swelling—Capecitabine—kidney cancer	0.00322	0.00813	CcSEcCtD
Phylloquinone—Sweating—Vincristine—kidney cancer	0.00322	0.00813	CcSEcCtD
Phylloquinone—Immune system disorder—Sunitinib—kidney cancer	0.00322	0.00813	CcSEcCtD
Phylloquinone—Necrosis—Doxorubicin—kidney cancer	0.00322	0.00812	CcSEcCtD
Phylloquinone—Flushing—Dactinomycin—kidney cancer	0.00314	0.00791	CcSEcCtD
Phylloquinone—Erythema—Sunitinib—kidney cancer	0.00311	0.00784	CcSEcCtD
Phylloquinone—Injection site pain—Doxorubicin—kidney cancer	0.00309	0.0078	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—IL2—kidney cancer	0.00309	0.00875	CbGpPWpGaD
Phylloquinone—Sweating—Gemcitabine—kidney cancer	0.00306	0.00771	CcSEcCtD
Phylloquinone—Hypersensitivity—Temsirolimus—kidney cancer	0.00301	0.00758	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—JUN—kidney cancer	0.003	0.00851	CbGpPWpGaD
Phylloquinone—Erythema—Dactinomycin—kidney cancer	0.00294	0.00742	CcSEcCtD
Phylloquinone—Hyperhidrosis—Everolimus—kidney cancer	0.00293	0.0074	CcSEcCtD
Phylloquinone—Sweating increased—Paclitaxel—kidney cancer	0.00292	0.00736	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—PIK3CA—kidney cancer	0.00286	0.00811	CbGpPWpGaD
Phylloquinone—Hypotension—Everolimus—kidney cancer	0.00284	0.00715	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Doxorubicin—kidney cancer	0.00278	0.00701	CcSEcCtD
Phylloquinone—Dyspnoea—Everolimus—kidney cancer	0.00271	0.00683	CcSEcCtD
Phylloquinone—Dizziness—Temsirolimus—kidney cancer	0.0027	0.00681	CcSEcCtD
Phylloquinone—Anaphylactic shock—Sorafenib—kidney cancer	0.00264	0.00665	CcSEcCtD
Phylloquinone—Dyspnoea—Erlotinib—kidney cancer	0.00261	0.00659	CcSEcCtD
Phylloquinone—Pain—Vinblastine—kidney cancer	0.00261	0.00657	CcSEcCtD
Phylloquinone—Inflammation—Doxorubicin—kidney cancer	0.0026	0.00657	CcSEcCtD
Phylloquinone—Pain—Everolimus—kidney cancer	0.0026	0.00655	CcSEcCtD
Phylloquinone—Immune system disorder—Gemcitabine—kidney cancer	0.00259	0.00652	CcSEcCtD
Phylloquinone—Dizziness—Pazopanib—kidney cancer	0.00254	0.00641	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—MME—kidney cancer	0.00254	0.00719	CbGpPWpGaD
Phylloquinone—Injection site reaction—Doxorubicin—kidney cancer	0.00251	0.00633	CcSEcCtD
Phylloquinone—Pain—Erlotinib—kidney cancer	0.0025	0.00632	CcSEcCtD
Phylloquinone—Erythema—Gemcitabine—kidney cancer	0.00249	0.00629	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—MAPK3—kidney cancer	0.00248	0.00703	CbGpPWpGaD
Phylloquinone—Sweating increased—Capecitabine—kidney cancer	0.00239	0.00604	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—MAPK1—kidney cancer	0.00236	0.00669	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—RPL14—kidney cancer	0.00236	0.00669	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—HSPD1—kidney cancer	0.00236	0.00669	CbGpPWpGaD
Phylloquinone—Dyspnoea—Sorafenib—kidney cancer	0.00235	0.00593	CcSEcCtD
Phylloquinone—Dyspnoea—Sunitinib—kidney cancer	0.00226	0.0057	CcSEcCtD
Phylloquinone—Pain—Sorafenib—kidney cancer	0.00225	0.00568	CcSEcCtD
Phylloquinone—Hypersensitivity—Vinblastine—kidney cancer	0.00225	0.00566	CcSEcCtD
Phylloquinone—Hypersensitivity—Everolimus—kidney cancer	0.00224	0.00564	CcSEcCtD
Phylloquinone—Flushing—Paclitaxel—kidney cancer	0.00223	0.00561	CcSEcCtD
Phylloquinone—Pain—Sunitinib—kidney cancer	0.00217	0.00547	CcSEcCtD
Phylloquinone—Immune system disorder—Paclitaxel—kidney cancer	0.00217	0.00546	CcSEcCtD
Phylloquinone—Anaphylactic shock—Vincristine—kidney cancer	0.00214	0.00541	CcSEcCtD
Phylloquinone—Phlebitis—Doxorubicin—kidney cancer	0.00213	0.00537	CcSEcCtD
Phylloquinone—Erythema—Paclitaxel—kidney cancer	0.00209	0.00526	CcSEcCtD
Phylloquinone—Hyperhidrosis—Vincristine—kidney cancer	0.00207	0.00523	CcSEcCtD
Phylloquinone—Pain—Dactinomycin—kidney cancer	0.00205	0.00518	CcSEcCtD
Phylloquinone—Anaphylactic shock—Gemcitabine—kidney cancer	0.00203	0.00513	CcSEcCtD
Phylloquinone—Dizziness—Vinblastine—kidney cancer	0.00202	0.00508	CcSEcCtD
Phylloquinone—Dizziness—Everolimus—kidney cancer	0.00201	0.00506	CcSEcCtD
Phylloquinone—Hypotension—Vincristine—kidney cancer	0.002	0.00505	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—TP53—kidney cancer	0.00198	0.00562	CbGpPWpGaD
Phylloquinone—Hyperhidrosis—Gemcitabine—kidney cancer	0.00197	0.00496	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—ACHE—kidney cancer	0.00195	0.00551	CbGpPWpGaD
Phylloquinone—Hypersensitivity—Sorafenib—kidney cancer	0.00194	0.0049	CcSEcCtD
Phylloquinone—Dizziness—Erlotinib—kidney cancer	0.00194	0.00489	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—EIF4EBP1—kidney cancer	0.00192	0.00545	CbGpPWpGaD
Phylloquinone—Hypotension—Gemcitabine—kidney cancer	0.0019	0.0048	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.00189	0.00478	CcSEcCtD
Phylloquinone—Hypersensitivity—Sunitinib—kidney cancer	0.00187	0.00471	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—PAX6—kidney cancer	0.00185	0.00525	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—CTSD—kidney cancer	0.00184	0.00522	CbGpPWpGaD
Phylloquinone—Pain—Vincristine—kidney cancer	0.00183	0.00463	CcSEcCtD
Phylloquinone—Flushing—Capecitabine—kidney cancer	0.00183	0.00461	CcSEcCtD
Phylloquinone—Dyspnoea—Gemcitabine—kidney cancer	0.00181	0.00457	CcSEcCtD
Phylloquinone—Immune system disorder—Capecitabine—kidney cancer	0.00178	0.00448	CcSEcCtD
Phylloquinone—Hypersensitivity—Dactinomycin—kidney cancer	0.00177	0.00446	CcSEcCtD
Phylloquinone—Dizziness—Sorafenib—kidney cancer	0.00174	0.0044	CcSEcCtD
Phylloquinone—Pain—Gemcitabine—kidney cancer	0.00174	0.00439	CcSEcCtD
Phylloquinone—Erythema—Capecitabine—kidney cancer	0.00171	0.00432	CcSEcCtD
Phylloquinone—Anaphylactic shock—Paclitaxel—kidney cancer	0.0017	0.0043	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—BCHE—kidney cancer	0.0017	0.0048	CbGpPWpGaD
Phylloquinone—Dizziness—Sunitinib—kidney cancer	0.00168	0.00423	CcSEcCtD
Phylloquinone—Hyperhidrosis—Paclitaxel—kidney cancer	0.00165	0.00415	CcSEcCtD
Phylloquinone—Hypotension—Paclitaxel—kidney cancer	0.00159	0.00401	CcSEcCtD
Phylloquinone—Hypersensitivity—Vincristine—kidney cancer	0.00158	0.00399	CcSEcCtD
Phylloquinone—Dyspnoea—Paclitaxel—kidney cancer	0.00152	0.00383	CcSEcCtD
Phylloquinone—Pain—Paclitaxel—kidney cancer	0.00146	0.00367	CcSEcCtD
Phylloquinone—Dizziness—Vincristine—kidney cancer	0.00142	0.00358	CcSEcCtD
Phylloquinone—Sweating—Doxorubicin—kidney cancer	0.00135	0.00342	CcSEcCtD
Phylloquinone—Hyperhidrosis—Capecitabine—kidney cancer	0.00135	0.00341	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—IGF2—kidney cancer	0.00131	0.00372	CbGpPWpGaD
Phylloquinone—Hypotension—Capecitabine—kidney cancer	0.00131	0.00329	CcSEcCtD
Phylloquinone—Hypersensitivity—Paclitaxel—kidney cancer	0.00125	0.00317	CcSEcCtD
Phylloquinone—Dyspnoea—Capecitabine—kidney cancer	0.00125	0.00314	CcSEcCtD
Phylloquinone—Pain—Capecitabine—kidney cancer	0.0012	0.00302	CcSEcCtD
Phylloquinone—Flushing—Doxorubicin—kidney cancer	0.00118	0.00297	CcSEcCtD
Phylloquinone—Immune system disorder—Doxorubicin—kidney cancer	0.00115	0.00289	CcSEcCtD
Phylloquinone—Dizziness—Paclitaxel—kidney cancer	0.00113	0.00284	CcSEcCtD
Phylloquinone—Erythema—Doxorubicin—kidney cancer	0.0011	0.00278	CcSEcCtD
Phylloquinone—Hypersensitivity—Capecitabine—kidney cancer	0.00103	0.0026	CcSEcCtD
Phylloquinone—Dizziness—Capecitabine—kidney cancer	0.000924	0.00233	CcSEcCtD
Phylloquinone—Anaphylactic shock—Doxorubicin—kidney cancer	0.000901	0.00227	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—POMC—kidney cancer	0.000876	0.00248	CbGpPWpGaD
Phylloquinone—Hyperhidrosis—Doxorubicin—kidney cancer	0.000871	0.0022	CcSEcCtD
Phylloquinone—Hypotension—Doxorubicin—kidney cancer	0.000842	0.00212	CcSEcCtD
Phylloquinone—Dyspnoea—Doxorubicin—kidney cancer	0.000803	0.00203	CcSEcCtD
Phylloquinone—Pain—Doxorubicin—kidney cancer	0.000771	0.00194	CcSEcCtD
Phylloquinone—Hypersensitivity—Doxorubicin—kidney cancer	0.000664	0.00167	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—CTNNB1—kidney cancer	0.000625	0.00177	CbGpPWpGaD
Phylloquinone—Dizziness—Doxorubicin—kidney cancer	0.000596	0.0015	CcSEcCtD
